CPI-006 is an immunomodulatory antibody that binds to immune cells, leading to activation of B cells and antibody production that we believe will destroy the SARS-CoV-2 virus.

Our Phase 1 study of CPI-006 demonstrated that it is safe and was associated with meaningful clinical benefits for mild or moderately ill COVID-19 patients. This includes no patients progressing to mechanical ventilation and a median time to discharge from hospital of 3.5 days¹. The Company is now enrolling a ~1,000 patient randomized, placebo-controlled Phase 3 study, in COVID-19 patients who are hospitalized with mild to moderate symptoms.

Based on pre-clinical and clinical data, we believe CPI-006 will be a safe and effective therapy that provides several unique advantages in the treatment of COVID-19:

• Single Low Dose – delivered via a convenient IV infusion over 10 minutes with the potential for subcutaneous administration in the future.
• Polyclonal – generates antibodies that bind to various subdomains, which is expected to make it more effective than passive monoclonal antibody therapy, and reduce the chance of immune evasion.
• Durable Immunity – sustains high titer antibody responses and increases memory B cells that are responsible for long-term immunity. 
• Reduced Immune Evasion – polyclonal antibody response to multiple viral proteins, and to variants, should reduce immune evasion.

This approach has the potential to be a foundational therapy for SARS-CoV-2, SARS-CoV-2 mutant variants, other coronaviruses or future pandemics.

¹ January 27, 2021

 

COVID-19 Publications and Presentations

Presentations